ASPAC III Acquisition Corp.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sze Wai Tsang
- Full Time Employees
- 1
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- The Sun’s Group Center, 29th Floor, 200 Gloucester Road Wan Chai Hong Kong
- IPO Date
- Nov 8, 2024
- CIK
- 0001890361
- Similar Companies
- Business
- A SPAC III Acquisition Corp. (Nasdaq: ASPC) is a blank check company incorporated in the British Virgin Islands whose principal business activity is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company offers no products or services of its own, focusing instead on identifying and pursuing initial business combination targets, particularly in environmental, sustainability and governance (ESG) and material technology sectors with enterprise values between $100 million and $600 million; it maintains a trust account funded by its initial public offering proceeds for use in such transactions. Founded on September 3, 2021, and headquartered at The Sun’s Group Center, 29th Floor, 200 Gloucester Road, Wan Chai, Hong Kong, the company completed a $55 million initial public offering of 5.5 million units at $10.00 per unit on November 8, 2024, led by Maxim Group LLC as sole book-running manager. In its most significant recent development, A SPAC III Acquisition Corp. entered into a merger agreement on May 23, 2025, with Bioserica International Limited, a British Virgin Islands company engaged in researching, developing, manufacturing, marketing, and selling bio-based antimicrobial materials through subsidiaries including BIOSERICA CO., LIMITED in Hong Kong, Bioserica (Nanjing) Antimicrobial Material Co., Ltd. in the People's Republic of China, and Nanjing Bioserica Era Antimicrobial Material Technology Group Co., Ltd.; the transaction contemplates a reincorporation merger followed by an acquisition merger, with aggregate consideration of $200 million payable entirely in stock comprising newly issued Class B ordinary shares at $10.00 per share plus up to 1,786,000 Class A ordinary shares. The proposed business combination, advised by Loeb & Loeb LLP for A SPAC III and Norton Rose Fulbright for Bioserica, remains subject to shareholder approval, regulatory clearances including CSRC and CAC filings in China, SEC registration statement effectiveness, and satisfaction of customary closing conditions, with no completion reported as of the latest available filings.
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
National Lipid Association and American Society for Preventive Cardiology Release Joint Clinical Perspective on The Importance of Low-Density Lipoprotein Cholesterol Measurement and Control as Performance Measures
Semantix Successfully Completes Business Combination with Alpha Capital
Alpha Capital Acquisition Company Shareholders Approve Proposed Merger Transaction with Semantix
Semantix Highlights Achievements In First Half of 2022
Semantix Announces Effectiveness of Alpha Capital’s F-4 Registration Statement
Semantix and Alpha Capital to Discuss Merger and Global Analytics Market in Virtual Fireside Chat
Semantix Welcomes Marcela Bretas as Chief Strategy Officer
Semantix to Host Virtual Management Presentation for Investors and Analysts May 18th, 2022
Semantix Launches Analytics Chat
Semantix Introduces Data & AI Marketplace to Semantix Data Platform
Alpha Capital Acquisition Company Files Registration Statement on Form F-4 in Proposed Merger with Semantix
Data Software Platform Semantix to Become Publicly Traded on Nasdaq via SPAC Merger with Alpha Capital
Alpha Capital Acquisition Company Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing April 12, 2021